The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback